Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm that Ulinastatin is a safe and effective drug and it
can reduce the incidence of postoperative hepatic failure in HCC patients. To evaluate that
Ulinastatin can improve survival in HCC patients or not.